Protein design Computationally engineered enzyme (gray) for enhanced stability, bound to DNA (red). 
Home » Funding & investments » Biomatter Designs raises €500k to develop AI for Generative Protein Design

Biomatter Designs raises €500k to develop AI for Generative Protein Design

Vilnius-born startup Biomatter Designs that pioneers the technologies for generative protein design,  has raised €500,000 in seed funding led by Practica Capital, accompanied by 70V and angel investors.  The raised capital will be used to further develop the company’s protein design technology and  product pipeline. 

Proteins are large, complex molecules that drive virtually every biological function. Naturally occuring  proteins aid biochemical reactions, transport materials within the cell, transduce chemical signals, and  play other crucial roles both in our bodies and around us. Proteins, when engineered to perform  specific functions (e.g. binding and neutralizing pathogens, converting industrial waste to useful  materials), have tremendous potential to solve some of humanity’s biggest challenges across  healthcare, food, agriculture and other industries.  

To accelerate the burdensome and resource-intensive process of protein engineering, Biomatter  Designs has developed a machine learning powered platform for next-generation computational  protein design. The platform analyses vast amounts of natural protein data to learn the complex rules  governing the functions of proteins and later applies the acquired knowledge to design new  protein molecules.

Laurynas Karpus

Laurynas Karpus, CEO of Biomatter Designs 

“Our company is striving to shift the paradigm in protein engineering” – says Laurynas Karpus, the CEO  of Biomatter Designs. “We are moving from classical protein discovery process to well-predictable  computational protein design. Classical methods often resemble searching for a needle in the haystack  – looking for the right answer in already existing or similar molecules. This takes a great amount of  time and requires loads of expensive and time-consuming experimental data. This is where our  technology steps in to intelligently augment the protein engineering process, allowing us to generate  new proteins right from the first atom. When it comes to solving problems in healthcare or  environmental sectors, we can’t afford to waste time.” 

With their computational platform, Biomatter Designs are able to generate novel enzymes and  protein therapeutics, which would otherwise be difficult to obtain by classical experimental and  computational approaches.  

“We are very excited to back this bold and long-term vision of Biomatter Designs. The interdisciplinary  approach combined with a strong and proven Lithuanian academic and industrial experience in  protein engineering, also adding new abilities of AI can lead to unprecedented outcomes. The  potential is truly vast”, – says Donatas Keras, Partner at Practica Capital

“70V is glad to have the opportunity to invest in ambitious A-grade talent like Laurynas and his team.  We see enormous potential for Biomatter Designs and are excited to be able to help with going to  market and accelerating the team’s expertise in enterprise sales.” -says Per Moller, Managing Partner  at 70V.

About Practica Capital 

Practica Capital is a dedicated Baltic VC focusing on investments in the Baltic (Lithuania, Latvia,  Estonia) and Baltic-origin (e.g. Baltic diaspora) ventures in Europe, in the early, early and growth  stages. The company manages three venture capital funds with a total size of more than €50M. Of  which the later Practica Venture Capital II Fund was established in the framework of the  implementation of the financial instrument “Development Fund I” of the Ministry of Economy and  Innovation of the Republic of Lithuania, financed from the European Regional Development Fund  (ERDF) managed by Invega. To date, Practica Capital has made more than 50 investments, including  the most prominent Lithuanian start-up ecosystem companies such as TransferGo, Trafi, CGtrader,  Nanoavionika, Ziticity, Oxipit and others. Find out more: https://practica.vc 

About 70V 

70V is a revenue accelerator focusing on B2B high growth companies with ambitious talent. Through  an individual accelerator program with investment up to EUR 300.000 they assist founders in  recruiting, training and setting up a specialized outbound sales team, as well as, fine tuning lead  generation and outreach. 70V acceleration fund was established in the framework of the  implementation of the financial instrument “Acceleration Fund” of the Ministry of Economy and  Innovation of the Republic of Lithuania, financed from the European Regional Development Fund  (ERDF) managed by Invega. To date, 70V has invested and accelerated 29 companies, for more  information visit: www.70V.com

3
Avatar

Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks